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Small molecules targeting
viral RNA
Thomas Hermann1,2*
Highly conserved noncoding RNA (ncRNA) elements in viral genomes and tran-
scripts offer new opportunities to expand the repertoire of drug targets for the
development of antiinfective therapy. Ligands binding to ncRNA architectures
are able to affect interactions, structural stability or conformational changes and
thereby block processes essential for viral replication. Proof of concept for target-
ing functional RNA by small molecule inhibitors has been demonstrated for mul-
tiple viruses with RNA genomes. Strategies to identify antiviral compounds as
inhibitors of ncRNA are increasingly emphasizing consideration of drug-like
properties of candidate molecules emerging from screening and ligand design.
Recent efforts of antiviral lead discovery for RNA targets have provided drug-like
small molecules that inhibit viral replication and include inhibitors of human
immunodeficiency virus (HIV), hepatitis C virus (HCV), severe respiratory syn-
drome coronavirus (SARS CoV), and influenza A virus. While target selectivity
remains a challenge for the discovery of useful RNA-binding compounds, a bet-
ter understanding is emerging of properties that define RNA targets amenable
for inhibition by small molecule ligands. Insight from successful approaches of
targeting viral ncRNA in HIV, HCV, SARS CoV, and influenza A will provide a
basis for the future exploration of RNA targets for therapeutic intervention in
other viral pathogens which create urgent, unmet medical needs. Viruses for
which targeting ncRNA components in the genome or transcripts may be prom-
ising include insect-borne flaviviruses (Dengue, Zika, and West Nile) and filo-
viruses (Ebola and Marburg). © 2016 Wiley Periodicals, Inc.
How to cite this article:
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INTRODUCTION
While the large majority of approved drugs acton protein targets, a chemically diverse set of
clinically important antibiotics bind selectively to the
RNA components (rRNA) of the bacterial ribosome
and thereby interfere with protein synthesis.1,2 These
antibiotics are derived from natural products and
provide a paradigm for targeting structured noncod-
ing RNA as an approach for therapeutic interven-
tion. Noncoding RNA (ncRNA) molecules are
increasingly recognized as key regulatory players of
biological processes3,4 in which they participate
based on their three-dimensional structure rather
than sequence. With their well-defined structure,
ncRNA folds provide potentially unique interaction
sites for selective small-molecule ligands that affect
the RNAs’ biological function. Outside the bacterial
ribosome, untranslated RNA regions as drug targets
have been pursued to discover therapeutics for viral
infections including those caused by the human
immunodeficiency virus (HIV)5 and hepatitis C virus
(HCV).6 These pathogens have single-stranded RNA
genomes which include structured noncoding regions
that play key roles in the viral infection cycle and
harbor potential binding sites for small molecule
inhibitors. The high conservation of untranslated
regions in viral genomes along with the absence of
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homologous host cell RNAs render structured viral
regulatory RNAs attractive targets for the develop-
ment of novel antiinfective drugs.7,8
Unlike typical inhibitor binding pockets in pro-
teins, sites for ligand recognition in RNA are often
shallow, highly solvated, and conformationally flexi-
ble. Therefore, structural and physicochemical prop-
erties of small molecule ligands for RNA differ
markedly from drugs targeting proteins.9 Clinically
used RNA-binding antibiotics are derived from natu-
ral products which, on average, are structurally more
complex, more hydrophilic, and contain a larger
number of hydrogen bond donors compared to drug-
like compounds.10 These molecular properties create
challenges in reconciling the design and optimization
of RNA-binding ligands with drug-like features
affecting absorption and distribution in vivo. Strate-
gies for the design and discovery of RNA-binding
ligands have been outlined long before the rise of
ncRNA,11–13 and comprehensive reviews on target-
ing RNA with small molecules have been published
regularly over the last years.14–16 Among the chemi-
cally diverse classes of RNA binders,9 recurring
scaffolds are found among derivatives of aminoglyco-
sides and planar intercalators including acridine and
phenothiazine (Figure 1).
Aminoglycosides are natural products from
Streptomyces soil bacteria that bind to the ribosomal
decoding site and exert antibiotic activity by interfer-
ing with bacterial protein synthesis.17 Amine func-
tional groups in aminoglycosides are protonated
under physiological conditions which results in an
overall cationic charge that promotes nucleic acid
binding but hampers cell penetration. Aminoglyco-
sides and their semi-synthetic derivatives have been
reported to promiscuously bind numerous ncRNA
targets9,14,15 including regulatory elements from
HIV, which over two decades ago were the first viral
RNAs to be investigated for small-molecule
inhibition.18–20 It has been suggested that aminogly-
cosides bind to RNA folds through structural electro-
static complementarity whereby positively charged
ammonium groups of the ligand recognize metal-ion-
binding pockets created by the RNA architec-
ture.21,22 Similarly, promiscuous binding to struc-
tured RNA has been observed for intercalating
compounds which contain flat aromatic scaffolds
such as acridine, phenazine and phenothiazine deri-
vatives. While early ligand-binding studies of ncRNA
focused on proof of concept and often involved pro-
miscuous binders including aminoglycosides and
intercalators, more recently, considerations of com-
pounds’ drug-likeness have been prominently
included in RNA targeting efforts. After all, some
RNA-binding drugs such as the oxazolidinone anti-
biotics provide a compelling reminder that properties
beneficial for RNA-targeting and drug-likeness may
be reconciled within a small molecule compound
(Figure 2).
Here, I focus on progress over the last 2 years
in the discovery and investigation of small molecule
ligands for viral RNA targets. Emphasis will be given
to ligands with molecular weight <750 D. Coverage
of the literature will occasionally go back further in
time for previously reported compound classes if
recent work has revealed new findings on mechanism
of action or provided structural insight. The review
of recently discovered ligands targeting viral RNA
will include a discussion of compounds’ physico-
chemical properties that affect drug-likeness.
VIRAL RNA AS A DRUG TARGET
Antibiotics derived from natural products including
aminoglycosides, macrolides, and tetracyclins have
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FIGURE 1 | Aminoglycosides such as neomycin and kanamycin,
and planar intercalators including derivatives of acridine, phenazine,
and phenothiazine are promiscuous binders of multiple RNA targets.
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FIGURE 2 | Linezolid is an oxazolidinone antibiotic (Zyvox®) that
binds at the peptidyl transferase center in the 23S rRNA of the
bacterial 50S ribosomal subunit and inhibits translation initiation.23
See the Box 1 for an explanation of molecular properties shown here
for linezolid.
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long been known to interfere with translation,24 and
these compounds provided powerful tools in the elu-
cidation of ribosome function.25 After decades of
mounting evidence that ribosome-inhibiting antibio-
tics do so by targeting the RNA components
(rRNA),26 Moazed and Noller demonstrated in 1987
that several classes of antibiotics bind directly to 16S
rRNA. These observations spurred efforts both in
academia and pharmaceutical industry to discover
small molecule ligands of other structured RNAs.
The HIV transactivation response (TAR) and Rev
response (RRE) RNA were the first viral regulatory
elements shown to bind small molecule compounds
that interfered with key steps of HIV
infection.18–20,27–30 The realization that the reper-
toire of therapeutic approaches to combat infections
may be expanded to inhibitors targeting viral RNA
components quickly gave birth to the notion of RNA
as an emerging drug target.11,31 Since then, interven-
tion by small molecules binding to ncRNA elements
has been explored for several viruses (Table 1). HIV
remains the most intensely studied virus, for which
multiple other functional RNA structures in the
genome besides the TAR and RRE sites have been
investigated as targets for small molecule ligands.
These include the dimer initiation sequence (DIS), the
packaging signal (Ψ), and the Gag/Pol frameshifting
signal. Previous reviews, including a comprehensive
article by Le Grice,5 cover the literature on efforts
targeting HIV RNA up to the year 2014.32–34 More
recent studies on discovery of inhibitors targeting the
TAR and RRE RNA by screening and scaffold-based
design will be discussed in the following
section (Figure 3 and Table 2).
Like HIV, HCV carries a (+) single-strand RNA
genome, which is not reverse transcribed, but directly
serves as a coding mRNA for viral proteins. Transla-
tion of the HCV genome is driven by a structured
RNA element in the 50 untranslated region (UTR)
which serves as an internal ribosome entry site
(IRES). A subdomain of the HCV IRES functions as
a conformational switch which has been identified as
the target site for small molecule inhibitors capturing
an extended conformation of the RNA and thereby
blocking viral translation.40 A previous review by
Dibrov et al. describes the discovery of HCV IRES-
directed inhibitors and structural as well as
mechanism-of-action studies that established the con-
formational switch motif as a privileged target site
for antiviral RNA-binders.6 In this review, I will
BOX 1
MOLECULAR PROPERTIES USED TO
PREDICT AND ASSESS DRUG-LIKENESS
ClogP, is the calculated logarithm of the parti-
tion coefficient between n-octanol and water
as a measure of compound hydrophilicity. Low
hydrophilicity is indicated by high log P values,
and values >5.0 have been implicated with poor
cell membrane permeation and absorption.
PSA, polar surface area, is the (calculated)
molecular surface created by polar atoms, pri-
marily oxygen and nitrogen and including the
attached hydrogen atoms. A PSA >140 Å2
causes poor cell membrane permeation.
HBD, is the number of hydrogen bond
donors, primarily hydrogens linked to oxygen
and nitrogen atoms. Hydrogen bond donors
improve solubility in water but impede cell
membrane permeation. The majority of
approved drugs contain 0–4 HBD (median: 1).10
BA, bioavailability, is the experimentally
determined fraction of a non-intravenously
administered drug dose that reaches systemic
circulation.
TABLE 1 | Viral RNA Targets
Virus Family Genome RNA Target Reviews
Human immunodeficiency virus (HIV) Retrovirus (+)ssRNA Transactivation response (TAR) element
Rev response element (RRE)
Dimer initiation sequence (DIS)
Packaging signal (Ψ) stem-loop 3 (SL-3)
Frameshifting signal
5, 32, 33, and 34
Hepatitis C virus (HCV) Flavivirus (+)ssRNA Internal ribosome entry site (IRES) 6
Severe acute respiratory syndrome
coronavirus (SARS CoV)
Coronavirus (+)ssRNA Frameshifting pseudoknot (PK) This review
Influenza A virus Orthomyxovirus (−)ssRNA RNA promoter for the viral RNA-dependent
RNA polymerase (RdRp)
35
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outline recent progress in the development of transla-
tion inhibitors targeting the HCV IRES (Figure 4 and
Table 3).
Viral ncRNA targets for small molecule ligands
which have emerged more recently and have not been
reviewed previously are the frameshifting pseudoknot
(PK) in the genome of the SARS coronavirus (CoV)47
and the promoter for the viral RNA-dependent RNA
polymerase in the (−)ssRNA genome of the influenza
A virus.48 Ligand discovery efforts and structural
studies of these targets will be discussed here
(Figures 5 and 6; Tables 4 and 5).
HIV Targets
The (+) single-strand RNA genome of HIV contains
multiple regulatory elements which are involved in
transcriptional regulation, reverse transcription, viral
protein translation, nucleocytoplasmic transport,
genome dimerization, and virion packaging.5 The
TAR element resides within the first 59 nucleotides
of the viral genome and serves as the binding site for
the Tat protein. Formation of the Tat/TAR complex
stimulates transcription elongation to yield full-length
transcripts by a complex mechanism that also
involves host cell factors.34 The Tat-binding site in
TAR consists of a conserved RNA stem-loop with a
pyrimidine-rich bulge (Figure 2) which is
TABLE 2 | Small Molecules Targeting HIV RNA
Compound Properties1 Target Discovery2 References
1 ClogP: 4.3
PSA: 52 Å2
HBD: 3
TAR Small-molecule microarray screening (SMM)
with fluorescently labeled RNA
36
2 ClogP: 0.4
PSA: 75 Å2
HBD: 5
TAR Fragment competition binding screening with
fluorescently labeled peptide ligand
37
3 ClogP: 0.2
PSA: 99 Å2
HBD: 5
TAR Scaffold-based design; fluorescence-based
target binding confirmation
38
4 ClogP: 7.1
PSA: 11 Å2
HBD: 0
RRE SL-IIB Competition binding screening with
fluorescently labeled peptide ligand of
FDA-approved drugs
39
5 ClogP: 5.2
PSA: 52 Å2
HBD: 0
RRE SL-IIB Competition binding screening with
fluorescently labeled peptide ligand of
FDA-approved drugs
39
1 See Box 1 for an explanation of molecular properties. ClogP and PSA were calculated with the Molsoft Molecular Properties calculator (Molsoft LLC, San
Diego).
2 See Box 2 for a description of common fluorimetric ligand binding assays for RNA targets.
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FIGURE 4 | The HCV IRES subdomain IIa RNA target. (a) Secondary structure of the subdomain IIa internal loop. Residue numbering
corresponds to the HCV genome sequence. (b) Crystal structure of the subdomain IIa RNA in complex with the benzimidazole IRES inhibitor
6 (Table 3).42 The ligand is shown in yellow stick representation. Positions of two magnesium ions are indicated by green spheres. (c) Target
recognition by hydrogen bonding and partial intercalation of benzimidazole 6 in the subdomain IIa RNA complex crystal structure. Structure image
was prepared from PDB coordinate file 3TZR.42
TABLE 3 | Small Molecules Targeting HCV IRES RNA
Compound Properties Discovery Reference
6 ClogP: 1.9
PSA: 47 Å2
HBD: 2
Mass spectrometry-based screening; FRET-based
target binding confirmation
6, 40, 41, and 42
7 ClogP: 3.9
PSA: 46 Å2
HBD: 2
Scaffold-based design; FRET-based target binding
confirmation
43 and 44
8 ClogP: 1.4
PSA: 53 Å2
HBD: 3
Scaffold-based design; FRET-based target binding
confirmation
43 and 45
9 ClogP: −1.9
PSA: 161 Å2
HBD: 7
Scaffold-based design; fluorescence-based target
binding confirmation
6 and 46
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conformationally dynamic but adopts a stable,
ordered structure in complex with Tat peptide, and
small molecule ligands. Disruption of the Tat/TAR
complex by competing ligands binding to the RNA
target blocks efficient HIV replication and was recog-
nized early as a potential path to the development of
antiviral drugs.19,30,34 Numerous studies have
focused on the discovery and design of TAR RNA-
binding inhibitors, including peptides, natural pro-
ducts such as aminoglycosides and synthetic small
molecules. These earlier efforts have been summar-
ized in several excellent reviews.5,14,15,32,34
More recently, Schneekloth and coworkers
have applied small molecule microarray (SMM)
screening of a fluorescently labeled TAR hairpin
model oligonucleotide to identify selective binders.36
A similar approach had been taken before by Disney
and Seeberger to explore interactions of aminoglyco-
sides with ribosomal A-site and group I intron ribo-
zyme RNA.51 In the recent study on HIV TAR, the
microarray-immobilized screening library was com-
posed of 20,000 drug-like small molecules that were
not biased for chemotypes considered to promote
RNA binding. A counter-screen was applied against
an unrelated RNA hairpin to exclude promiscuous
binders. The SMM screen returned a low hit rate of
0.02%, excelled with a low false-positive rate, and
eventually delivered a confirmed hit compound (1, -
Table 2) with reasonable drug-like properties,
anti-HIV activity in T-lymphoblasts (EC50 value of
28 μM), as well as low cytotoxicity. The thienopyri-
dine derivative 1 is surprisingly hydrophobic for an
RNA-binding ligand and similar chemotypes have
not been reported before as TAR-binders. It remains
to be seen if the potency of thienopyridine derivatives
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can be improved to furnish lead candidates for the
development of antiviral drugs targeting the HIV
TAR. Nevertheless, the SMM screening approach
has proven to be a promising method for the discov-
ery of drug-like ligands for RNA and fruitful applica-
tion to other ncRNA targets is expected.
A fragment-based screening approach to identify
ligands of the HIV TAR element has been described
by Göbel and colleagues who interrogated a set of
29 small molecules that were selected to represent
molecular motifs beneficial for RNA recognition.37
The fragments were rich in chemotypes that provide
hydrogen bond donors and included amines, ami-
dines, and guanidines as well as benzene rings for
stacking interactions. A fluorimetric competition assay
(Box 2) was used to determine ligand binding by test-
ing for the ability of a compound to displace a dye-
labeled Tat peptide from a TAR model RNA. Seven
small molecules from the screening set were found to
compete with Tat peptide binding at TAR with IC50
values between 40 and 70 μM, including the quinazo-
line 2 shown as an example in Table 2 (IC50 value of
60 μM). At least two of the hit compounds had been
identified previously as inhibitors of Tat/TAR com-
plex formation and were shown to downregulate Tat
transactivation in a cell-based assay.30 While cellular
activity was not tested in the fragment screening
approach reported by Göbel et al., one-dimensional
1H NMR was used to confirm ligand interaction with
the RNA target by monitoring changes in imino-
proton signals upon titration with compound. As a
consequence of the composition bias of the screening
set with small molecules rich in hydrogen bond
donors, the hit compounds tended to exceed the num-
ber of hydrogen bond donors of typical drug-like
molecules. However, fragment incorporation for con-
struction of larger ligands in the future would reduce
the number of hydrogen bond donor sites.
Benhida and coworkers pursued a design
approach for TAR RNA-binding ligands based on
amino-phenylthiazole derivatives38 which are nucleo-
base analogs that were proposed to interact with A–
U pairs through hydrogen bonding of the amino-
thiazole scaffold at the Hoogsteen edge of adenine.52
A set of 15 conjugates of the amino-phenylthiazole
scaffold (termed ‘S nucleobase’; highlighted in blue in
compound 3, Table 2) with different natural amino
acids and dipeptides were synthesized and tested for
RNA target binding as well as antiviral activity in
cell culture. As a consequence of the design paradigm
focusing on a scaffold for nucleobase-like interaction,
the resulting compounds were hydrophilic and car-
ried a larger number of hydrogen bond donor
groups. Ligands of the TAR element were identified
by monitoring fluorescent changes upon compound
titration to a terminally dye-labeled TAR model oli-
gonucleotide (Box 2). S nucleobase conjugates of
arginine, lysine, and histidine were found to tightly
TABLE 4 | Small Molecule Targeting SARS CoV Frameshifting Pseudoknot
Compound Properties Discovery Reference
10 ClogP: 2.7
PSA: 60 Å2
HBD: 1
Virtual screening by docking; SPR-based target binding
confirmation
47 and 50
TABLE 5 | Small Molecules Targeting Influenza A Virus RNA Promoter
Compound Properties Discovery Reference
11 ClogP: 1.1
PSA: 69 Å2
HBD: 3
NMR-based fragment binding screening 48
12 ClogP: 1.8–2.3
PSA: 73–74 Å2
HBD: 2
Scaffold-based design; NMR-based target
binding confirmation
49
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bind the TAR RNA. However, only the histidine
derivative 3 (Table 2) was a selective TAR binder
(Kd = 17 μM) whose affinity for the target was not
diminished in the presence of other nucleic acids. The
arginine and lysine conjugates showed better interac-
tion with TAR RNA (Kd = 2.4 and 7.5 μM,
respectively) but binding was promiscuous and
strongly affected by the presence of competitor
nucleic acids. Perhaps attesting to a correlation of
target selectivity and biological activity, only the his-
tidine derivative 3 showed antiviral activity in HIV-
infected human cells (IC50 = 0.41 μM). It is not clear
why the viral inhibition potency of 3 exceeds the tar-
get binding affinity by 40-fold. This finding suggests,
however, that compound 3 may act on other targets
in addition to the TAR RNA.
Among recently described structurally complex
ligands of the TAR RNA whose molecular weight
exceeds 750 D are aminoglycoside-benzimidazole
conjugates developed by Arya, Appella, and
coworkers,53,54 and nucleobase-linked aminoglyco-
sides synthesized by Hamasaki and colleagues.55,56
Aminoglycoside conjugates in both series are highly
hydrophilic compounds which contain over 10 hydro-
gen bond donors and have nanomolar affinity for the
TAR target. Antiviral activity of the conjugate com-
pounds in cells has not been reported.
The HIV RRE element is located within a
stretch of approximately 250 nucleotides in the sec-
ond intron of the viral genomic RNA and has a more
complex structure than the TAR motif. The stem-loop
IIB (SL-IIB), which is formed by residues 45–75 of the
HIV-1 RRE (Figure 3), serves as a high-affinity bind-
ing site for the viral Rev protein. Rev binding to RRE
is required for the nucleocytoplasmic export of full-
length and singly spliced viral transcripts. Disruption
of the Rev–RRE interaction has been explored for
over two decades as a strategy for the development of
antiviral therapies. Past efforts to discover Rev-
competitor ligands for the RRE RNA have largely
been focused on ligand-based design (summarized in
comprehensive reviews14,32). Only two studies have
been published of small molecule high-throughput
screens for inhibitors targeting the Rev–RRE com-
plex.57,58 None of these approaches has yet produced
bona fide inhibitors of in vitro Rev–RRE complex for-
mation that show antiviral activity in cells. A recent
study by Rana and colleagues has shown that post-
transcriptional modification of HIV-1 RRE by N6-
methylation of adenine bases in SL-IIB plays a critical
role in the activity of the RRE/Rev complex,59 which
serves as a poignant reminder that authentic model
systems are requisite for the study of RNA targets.
Gallego and coworkers have identified inhibi-
tors of HIV RNA biogenesis that block Rev–RRE
interaction in a binding competition screen (Box 2)
of 1120 FDA-approved drugs against complex for-
mation between a fluorescently labeled Rev peptide
and the RRE SL-IIB RNA target.39 Antiviral activity
of hit compounds in cells was confirmed for
BOX 2
COMMON FLUORESCENCE-BASED
ASSAYS TO DETERMINE LIGAND
BINDING TO RNA TARGETS
Terminal target labeling assays rely on the
assumption that ligand binding results in
changes of RNA conformation or dynamics and
thereby translate into dose-dependent fluores-
cence changes of a dye terminally conjugated
at a target oligonucleotide. Unlike ligand com-
petition assays, testing with terminally labeled
oligonucleotide models usually does not resolve
binding sites.
Competition with labeled tool ligand assays
monitor displacement of a fluorescently labeled
tool ligand from a specific binding site of an
RNA target. Depending on the target, the tool
ligand may be a small molecule, peptide, pro-
tein, or nucleic acid. For implementation, a
good understanding of competition kinetics is
required when tool ligands have slow off-rates
which may require long incubation times. The
dynamic range for detectable compound affi-
nities is limited by the affinity of the tool ligand
and it may be challenging to identify weak
binders.
Incorporation of fluorescent nucleoside ana-
log assays rely on monitoring fluorescence
changes originating from changes of RNA con-
formation, dynamics or direct quenching upon
ligand binding to a model oligonucleotide that
carries a fluorescent nucleobase incorporated in
proximity of a specific binding site. Direct infor-
mation on binding site specificity is obtained
but modification of the target by incorporation
of a chemically modified nucleoside analog is a
concern.
FRET (Förster resonance energy transfer)
assays use RNA targets labeled with a pair of
FRET dyes. Efficiency of the FRET effect depends
on the sixth order of the distance between
donor to acceptor and provides a sensitive
measure of ligand-induced conformational
changes in an RNA target.
WIREs RNA Small molecules targeting viral RNA
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clomiphene (4, Table 2) and cyproheptadine (5)
which inhibited HIV transcription and affected levels
of spliced versus unspliced viral transcripts to an
extent that was consistent with their ability to disrupt
Rev–RRE complex function in vitro. Clomiphene (4),
a selective estrogen receptor modulator, inhibited
Rev peptide binding to RRE SL-IIB with an IC50
value of 3.5 μM and had antiviral activity with an
EC50 value of 4.3 μM in the cell-based assay. The
corresponding values for cyproheptadine (5), an anti-
histamine H1 receptor antagonist, were 4.2 and
17 μM (IC50/EC50). Interaction of clomiphene (4)
was highly specific for the RRE SL-IIB target while
target binding of cyproheptadine (5) was significantly
compromised in the presence of competitor tRNA or
DNA. NMR spectroscopic studies revealed the G-
rich internal loop in the lower stem of SL-IIB as the
interaction site for 4 and 5, which overlaps with the
binding region of Rev and is consistent with the pro-
posed mechanism of inhibition by ligand competi-
tion. Direct interaction of these hydrophobic drugs
with an RNA target may appear unexpected and dis-
pels the notion that a large number of hetero-atom
hydrogen bond donors and acceptors are required to
confer ‘RNA-friendly’ properties to small molecule
ligands. After all, hydrogen bond donors are absent
in either of the compounds 4 and 5.
HCV IRES
Translation of the HCV genomic RNA is driven by
an IRES element that recruits ribosomes directly at
the viral start codon without the need for most host
cell initiation factors. The unique role of the viral
IRES and its high conservation in clinical isolates has
led to recognition of this ncRNA as a potential drug
target.60,61 High throughput screening of over
200,000 compounds for inhibition of IRES function
in cell-based reporter translation assays led to the dis-
covery of phenazine derivatives62 and biaryl guani-
dines63 which had moderate selectivity for the viral
translation target. While the structures of compounds
from these chemical series suggest that they may
interact with the IRES RNA, target binding or antivi-
ral activity were not reported in these early studies.
An important breakthrough was achieved by Seth
and colleagues who used mass spectrometry-based
screening of 180,000 compounds to identify 2-
aminobenzimidazole derivatives as ligands binding
the internal loop RNA of subdomain IIa in the HCV
IRES (Figure 4(a)).41 Lead optimization driven by
structure-activity relationship data furnished com-
pound 6 (Table 3) which had an affinity of 0.9 μM
(Kd) for the IRES target (determined by mass
spectrometry) and inhibited HCV in cell culture with
an EC50 value of 3.9 μM while showing no cytotox-
icity up to 100 μM concentration.41 Mechanism of
action studies of 2-aminobenzimidazoles revealed
that these compounds act as allosteric inhibitors of
an RNA conformational switch in the IRES subdo-
main IIa.40 In contrast to metabolite-sensing ribos-
witches, the HCV IRES subdomain IIa motif is
representative of a new class of RNA conformational
switches that are structurally well-defined in both
ligand-free and bound states and may represent the
simplest form of ligand-responsive, purely mechani-
cal switches in nucleic acids.64
The synthetic benzimidazoles are fortuitous
ligands of a recognition site for guanosine,65 and
capture the subdomain IIa target in an extended con-
formation which blocks viral translation initiation by
the IRES element. X-ray crystallography has pro-
vided structural insight into the conformational states
of the subdomain IIa switch in the absence66 and
presence42 of inhibitor ligand. In the extended con-
formation of the switch, the bound inhibitor is
encapsulated by a deep solvent-excluded RNA
pocket that resembles ligand interaction sites in apta-
mers and riboswitches (Figure 4(b) and (c)). Depth,
structural complexity, and physicochemical proper-
ties of the ligand binding pocket distinguish the IRES
IIa switch from other viral RNA targets and suggest
that discovery of drug-like inhibitors is feasible. A
FRET-based assay (Box 2) was developed to investi-
gate ligand binding to subdomain IIa and screen for
viral translation inhibitors that capture the RNA
switch in an extended state.40,43 In a different assay,
which monitors fluorescence changes of a nucleoside
analog (Box 2) incorporated in the internal loop of
subdomain IIa, diaminopiperidines such as com-
pound 9 (Table 3) were found to bind the IRES tar-
get as well.46 Unlike the 2-aminobenzimidazoles, the
diaminopiperidine ligands lock the RNA conforma-
tional switch in a bent state and thereby inhibit viral
translation initiation. A recent review summarizes
comprehensively studies on 2-aminobenzimidazole
and diaminopiperidine HCV translation inhibitors.6
The diaminopiperidines are hydrophilic com-
pounds which contain numerous hydrogen bond
donors, which suggests that polar interactions play
an important role for RNA target recognition. As a
consequence, binding affinity of compounds such as
9 for the subdomain IIa RNA target decreases with
ionic strength of the medium.46 In contrast, 2-
aminobenzimidazoles such as inhibitor 6 have more
drug-like properties, but contain basic amino groups
that are positively charged under physiological condi-
tions. Moreover, construction of the pyran ring in
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6 required a lengthy synthetic route that hampered a
deep exploration of this chemical series.41,67 We have
recently designed second generation ligands for the
guanosine binding pocket in the HCV IRES subdo-
main IIa target which address the shortcomings of
the original 2-aminobenzimidazole derivatives. In an
approach to maintain the nonplanarity of benzimida-
zole ligands, which is introduced by the sp3 carbon
centers in the pyran ring of ligands such as 6, we
have designed N1-coupled aryl derivatives repre-
sented by compound 7. Sterical hindrance of the N1
aryl substituent induces a twisted conformation with
an overall nonplanar shape of the resulting com-
pounds.44 In another set of analogs, we have
replaced the basic imidazole ring in the first genera-
tion ligands with the less basic oxazole system.45 The
resulting ligands, exemplified by compound 8, were
accessible through straightforward synthetic routes
and displayed good drug-like properties. However,
none of the synthesized N1-coupled aryl benzimida-
zoles44 or oxazole derivatives45 had an affinity for
the IIa RNA superior to the original 2-aminobenzimi-
dazoles. The best ligands in the new compound series
showed EC50 values for target binding of
74–120 μM.44,45 A computational molecular dynam-
ics (MD) study of 2-aminobenzimidazoles in complex
with the IRES IIa RNA inspired the design of tetracy-
clic dipyrroloindoles which were proposed as rigid,
less basic ligand candidates.68 However, synthesis or
testing of the in silico designed compounds was not
reported. The structural plasticity of the HCV IRES
subdomain IIa illustrates the challenges facing com-
putational approaches for RNA targets in general.
Large conformational changes in the IIa RNA target
upon ligand binding, accompanied by extensive rear-
rangement of base stacking, were unexpected and
likely beyond the predictive ability of current compu-
tational approaches. The relative success of MD stud-
ies reproducing the conformational rearrangement
and benzimidazole ligand binding of the IIa
RNA68,69 may be attributed to the fact that experi-
mental waypoints in the form of high-resolution crys-
tal structures were available to guide the calculations.
Challenges of large conformational changes in RNA
targets are compounded by the dominant electro-
static interactions in the anionic polymer
and concurrent impact of counter-ion binding and
hydration,70 which are recognized as the Achilles’
heel of computational approaches for RNA.71
While this review focuses on small molecule
ligands with a molecular weight <750 D, brief men-
tion should be made of copper-binding metallopep-
tides that have been developed to target domains of
the HCV IRES and damage the RNA through metal-
catalyzed cleavage.72–74 These peptides contain a
conserved 3-amino acid motif of Gly–Gly–His which
coordinates Cu, linked to a recognition sequence that
confers RNA target binding specificity. Cu-
metallopeptides with 7–27 amino acids have been
reported to bind IRES domains and inhibit HCV in
cell culture with submicromolar affinity.72–74
SARS CoV Frameshifting PK
Programmed ribosomal frameshifting is an evolution-
ary strategy to maximize the coding content of gen-
omes by providing a mechanism that allows
translation of overlapping reading frames.75 Some
RNA viruses, including HIV and the severe acute res-
piratory syndrome CoV (SARS CoV), regulate the
transition of highly expressed structural proteins to
viral enzymes expressed at low levels by a −1 frame-
shift during translation. Translational frameshifting
is triggered by the interplay of two RNA motifs
which include a slippery sequence where the reading
frame change occurs, followed by a structured region
that stalls the ribosome. The structured frameshift
motif in HIV consists of a long RNA hairpin with an
internal loop, which has been explored in ligand tar-
geting approaches that were aimed at stabilizing or
disrupting the RNA fold. Earlier studies on the HIV
target have been discussed in recent comprehensive
reviews by Le Grice, Brakier-Gingras, and cowor-
kers.5,33 In SARS CoV, translation of viral proteins
required for replication including the RNA-
dependent RNA polymerase is initiated by a −1 pro-
grammed frameshift which is triggered by a three-
stemmed RNA PK (Figure 5).76,77
Park and colleagues used an in silico screening
approach to identify ligands of the SARS CoV PK.47
Since the three-dimensional structure of the target
has not been determined yet, docking of compounds
was performed to a model of the RNA PK. Among
hit compounds identified in the screen, the drug-like
1,4-diazepane derivative 10 (‘MTDB’, Table 4) was
reported as an inhibitor of translational frameshifting
both in vitro and in a cell-based assay
(IC50 = 0.45 μM).47 Direct interaction of 10 with the
SARS CoV PK was demonstrated recently by Ritchie
and coworkers who measured ligand binding to the
RNA target by surface plasmon resonance (SPR) and
determined a Kd of 210 μM.50 They went on to per-
form single-molecule unfolding experiments with the
PK in the absence and presence of 10, which led to
the conclusion that ligand binding reduces the con-
formational plasticity of the RNA fold and thereby
affects ribosomal frameshifting. Efficiency of frame-
shifting is not determined by thermodynamic stability
WIREs RNA Small molecules targeting viral RNA
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of the PK or impact on ribosomal pausing but rather
by the ability of the RNA fold to adopt alternate
conformations and structures.78 Therefore, ligand
binding may affect translational frameshifting
through a complex mechanism that only partially
relies on stabilization of the PK RNA. For some of
the previously identified inhibitors of HIV transla-
tional −1 frameshifting, it has been suggested that
their promiscuous RNA-binding ability may affect
ribosomal RNA rather than the viral genomic frame-
shifting signal.33 Interaction with multiple targets
may play a role for the inhibitory action of 10 as
well, which may account for the over 450-fold
higher potency of this compound as a frameshifting
inhibitor in a cell-based assay47 compared to its
RNA binding affinity.50
Influenza A Virus RNA Promoter
The influenza A orthomyxovirus harbors a single-
stranded RNA genome that contains eight negative-
sense segments (vRNA) which encode the viral pro-
teins and are used as templates for transcription to
mRNA and replication into complementary strands
(cRNA). The viral RNA-dependent RNA polymerase
recognizes79 a partial duplex structure that forms
through circularization of vRNA by hybridization
between conserved nucleotides at the 50 and 30 end of
each segment.80,81 The resulting RNA duplex
(Figure 6(a)) is stable under physiological condi-
tions82 and serves as a promoter for transcription
and replication. Investigations of the RNA promoter
structure by NMR revealed a bifurcated interaction
of a uracil base hydrogen bonding with two consecu-
tive adenine residues in the opposite strand.83 This
motif in conjunction with a neighboring noncanoni-
cal AoC base pair induces widening of the major
groove of the RNA promoter helix near the polymer-
ase initiation site. Since unique structural features
introduced by internal loops and noncanonical base
pairs have previously been shown to provide ligand
recognition sites in duplex RNA, it is conceivable
that selective compound binding to the influenza A
RNA promoter might interfere with polymerase
interaction and prevent viral replication. Inhibitors
that interfere with viral gene expression by binding
to the RNA promoter would provide a novel mech-
anism of action for the development of anti-influenza
drugs. In an earlier study, Choi and coworkers used
a competition assay with a fluorescently labeled
binder (Box 2) to test aminoglycoside binding at the
influenza A RNA promoter.84 Affinity in the low
micromolar range (Kd = 2.7–33 μM) was reported
for various aminoglycosides but the impact of ligand
binding on the promoter function was not
investigated.
More recently, Varani and coworkers per-
formed an NMR-based fragment binding screen of
4279 compounds against an oligonucleotide model
of the influenza A RNA promoter (Figure 6(a)).48
Among seven initial hit compounds which led to
changes in the RNA imino proton signals observed
by NMR, the drug-like amino-quinazoline 11
(‘DPQ’, Table 5) had the highest affinity at a Kd of
50–60 μM.48,49 NMR spectroscopy was further used
to obtain a model of the promoter in complex with
11 (Figure 6(b) and (c)). Ligand binding is observed
in a widened RNA major groove at the internal loop
formed by the bifurcated U < A/A motif. The NMR
model of the promoter complex suggests that 11
interacts with the RNA target mainly by contacts of
the methoxy substituents which are positioned
closely to residues of the internal loop motif
(Figure 6(c)). The researchers point out that methoxy
group protons in 11 are within hydrogen bonding
distance to A11, A12, G13, and C22.48 Hydrogen
bond formation involving carbon-attached donors
interacting with oxygen (CH  O) and nitrogen
(CH  N) acceptors is unusual but has precedent in
biomolecular structures.85,86 While such interactions
are weak and may be rare in small molecule recogni-
tion of RNA folds, CH  O hydrogen bonds invol-
ving an aryl-methoxy donor have been observed
contributing to binding of a 6-O-methylguanine
ligand in crystal structures of purine riboswitches.87
For several natural product antibiotics that contain
aryl-methoxy groups, including anisomycin and
puromycin,9 crystal structures of ribosome-bound
complexes are available. However, the diffraction
resolution of the data used to obtain these structures
limit conclusions on potential hydrogen bond interac-
tions of the methoxy groups. Emetine, an antiproto-
zoal drug that binds to the eukaryotic ribosome,
contains aryl-o-dimethoxy-scaffolds comparable to
the o-dimethoxy-quinazoline in 11. A recent cryo-
EM structure of a Plasmodium 80S ribosome in com-
plex with emetine shows the aryl-methoxy groups
solvent-exposed and oriented away from the RNA,
however, with a limited resolution at 3.2 Å.88
A cell-based assay that measured cytopathic
effect inhibition demonstrated antiviral activity of the
RNA promoter-targeting compound 11 against the
H1N1 and H3N2 strains of influenza A as well as
influenza B with EC50 values of 72, 275, and
114 μM, respectively. In a cell-based direct viral rep-
lication assay, which monitored luciferase reporter
expression from a modified H1N1 influenza A virus,
compound 11 inhibited replication at an EC50 value
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of 435 μM48 (reported as 549 μM in a later publica-
tion49). At the same time, cytotoxicity was not
detected at compound concentrations over 500 μM.
In a follow-up study, Bottini and colleagues synthe-
sized and tested 16 analogs of 11.49 Among the
second-generation amino-quinazoline analogs, a set
of four structurally related compounds (12a,b,c,d;
Table 5) stood out for their improved binding affinity
to the influenza A RNA promoter target (Kd = 34–44
μM by NMR) and activity as inhibitors of viral rep-
lication (IC50 = 44–158 μM).49 The authors note
that a possible direct inhibition of the viral RNA-
dependent RNA polymerase by the amino-
quinazoline derivatives cannot be ruled out and has
yet to be investigated. None of these compounds
showed cytotoxicity up to the maximum tested con-
centration of 250 μM.
CONCLUSION
Viruses have compact, highly streamlined genomes
which provide only a limited number of protein tar-
gets for therapeutic intervention in viral infections.
The repertoire of drug targets may be expanded by
targeting structured RNA elements in the genomes
and transcripts of viral pathogens. In this review, I
have discussed recent progress in the discovery of
small molecule-targeting approaches directed at
structured RNA motifs in the genomes of HIV,
HCV, SARS CoV, and influenza A, which represent
a variety of virus families. Regulatory sequences in
viral genomes and transcripts stand out for their
conservation in clinical isolates which promise a
high barrier to resistance development against inhi-
bitors targeting these structured RNA elements.
Nevertheless, criteria of drugability have to be
thoughtfully applied to select RNA targets for small
molecules in the development of novel antiviral
therapies. Such considerations are more important
than ever in light of an unprecedented surge of new
ncRNA species emerging as key participants in bio-
logical processes.4 Structurally well-defined, deep
and solvent-excluded ligand binding pockets are rare
in RNA folds but provide the most promising
opportunities for discovery of drug-like inhibitors
on par with drugs targeting viral proteins. Among
the viral RNA motifs discussed here, the HCV IRES
subdomain IIa perhaps best embodies such advanta-
geous characteristics of a drug target, but is also
unique with respect to its function as a conforma-
tional switch that harbors a proper ligand binding
pocket. Similar RNA switch motifs have been dis-
covered in over 10 other flavi- and picornaviruses,64
however, none of which rise to a level of threat as a
human pathogen comparable to HCV. Outside
viruses, comparable deeply encapsulating ligand
binding pockets in RNA are found in bacterial
riboswitches which are being exploited as targets for
antibiotics discovery.89,90
Lessons from efforts of ligand discovery for
structured RNA elements, including regulatory
motifs in the viruses discussed here, bacterial rRNA,
riboswitches, and other ncRNA may inspire the
future search for inhibitors targeting RNA motifs in
a wider range of human-pathogenic viruses. Table 6
lists a selection of viruses with a high human disease
burden for which structured RNA elements have
been shown to play a role during infection.
Insect-borne flaviviruses, including Dengue,
West Nile, and Zika viruses, harbor multiple-
structured RNA motifs which are involved in repli-
cation, translational control, and host adaptation.94
TABLE 6 | Viruses Carrying Potential RNA Targets for Small Molecule Ligands
Family Examples Genome Potential RNA Targets
Insect-borne flavivirus
(arbovirus)
Dengue (DENV), West
Nile (WNV), Yellow
fever (YFV), Zika
(ZIKV), Tick-borne
encephalitis (TBEV)
(+)ssRNA 50 UTR (including RNA promoter in stem-loop A, SLA; RNA long-range
interacting stem-loop B, SLB)91,92
Structured elements in the coding region (including capsid coding region
hairpin, cHP; pseudoknot C1)93
30 UTR (including RNA long-range interacting structures)91,92,94,95
30 UTR-derived ncRNA (including subgenomic flavivirus RNA, sfRNA)96,97
Filovirus Ebola (EBOV), Marburg
(MARV)
(−)ssRNA RNA promoter for the viral RNA-dependent RNA polymerase (RdRp)98–100
Structured intergenic regions (IGR) of the viral genome100,101
50 and 30 UTR in viral transcripts102,103
Herpesvirus Kaposi’s sarcoma
associated
herpervirus (KSHV)
dsDNA IRES in the transcript for the viral homolog of the FLICE inhibitory protein
(vFLIP)104–106
Polyadenylated nuclear (PAN) noncoding RNA107
Hepadnavirus Hepatitis B (HBV) ds/ssDNA Encapsidation signal epsilon of viral pregenomic RNA (pgRNA)108
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Several of the flavivirus RNA elements have
features of conservation and structural complexity
comparable to the viral RNA motifs discussed in
this review and may be tractable targets for small
molecule ligand discovery. A variety of potential
drug targets in structured RNA elements is also
found in filoviruses, which include the etiologic
agents of Ebola and Marburg hemorrhagic fever.
Replication of these negative-sense RNA viruses
relies on a structured RNA promoter element that
consists of a large hairpin involving nucleotides
1–55 in the 50 terminus of the viral genome whose
secondary structure has been established by chemi-
cal probing.98,99 The 30 terminus of the filovirus
genome does not interact with the 50 end, unlike in
the RNA promoter of influenza A virus which also
has a negative-sense ssRNA genome. Filovirus gen-
omes consist of a nonsegmented RNA that encodes
reading frames for seven structural proteins which
are separated by long intergenic regions (IGR). The
IGR between virus proteins VP30 and VP24 has
been suggested to fold into a two-armed stem-loop
structure that includes a complex RNA four-way
junction.101 Transcription of viral genes involves
the VP30 nucleocapsid protein as an anti-
termination factor that binds to a hairpin loop at
the transcription start site.102,103 Viral transcripts
have long 50 UTR elements that derive from the
IGR and contain hairpin loop structures which
may play a role in transcriptional regulation and
translational control.109 Examples of attractive
RNA targets for ligand inhibition are also found in
DNA viruses. Among them is the oncogenic Kapo-
si’s sarcoma associated herpesvirus (KSHV) which
is a common cause of malignancies in AIDS
patients. Translation of the viral homolog of the
FLICE inhibitory protein (vFLIP), a key player
involved in KSHV-induced tumorigenesis,110 is
initiated at an IRES element that adopts a complex
RNA secondary structure including a conserved
segment of 252 nucleotides.104,111 Functional and
chemical probing analysis of the vFLIP IRES
revealed an independently folding RNA core
domain linked to flexibly linked hairpin motifs
which provide several structurally well-defined sites
for ligand targeting.106 KSHV also encodes a 1077
nucleotide polyadenylated nuclear (PAN) ncRNA,
which is the most abundant transcript produced
from the viral genome during lytic replication.107
PAN RNA is essential for viral propagation, and
its accumulation relies on posttranscriptional stabi-
lization involving a cis-acting RNA motif which
acts as an enhancer of nuclear retention element
(ENE).112 The ENE is a 79 nucleotide motif in the
PAN 30 terminus which sequesters in cis the PAN
poly(A) tail in a unique triple helix structure that
protects the ncRNA from decay and leads to accu-
mulation of PAN.113 Both, the ENE hairpin struc-
ture, which contains a uridine-rich, large internal
loop, and the ENE-poly(A) triple helix complex are
potential targets for small molecule ligands that
may interfere with KSHV replication. One final
example for a tractable RNA target in a DNA virus
is the pregenomic RNA (pgRNA) of Hepatitis B
virus (HBV) which serves as an intermediate tem-
plate in viral replication through reverse transcrip-
tion.114 Prior to reverse transcription, the HBV
pgRNA is sequestered together with polymerase
into subviral particles. Both encapsidation and ini-
tiation of reverse transcriptase require a conserved
sequence in the 50 terminal region of the pgRNA
which folds into a stem loop structure with a
uridine-rich internal loop referred to as the epsilon
encapsidation signal.108,115–117 While small mole-
cule ligands of this RNA motif have not been
reported yet, RNA decoys of the epsilon sequence
have been developed that sequester reverse tran-
scriptase, which provided proof-of-principle that
disruption of the pgRNA-polymerase interaction
suppresses HBV replication.118
In conclusion, while preventive vaccines and
drugs that target well-characterized viral proteins
such as polymerases and proteases are proven routes
to antiviral therapy, structured RNA motifs in viral
genomes and transcripts provide new opportunities
to expand the repertoire of targets for the develop-
ment of antiinfective therapy. Selection of viral struc-
tured RNA elements for inhibitor discovery requires
critical evaluation for properties that define targets
for drug-like ligands. After all, just as some proteins
that participate as key players in disease processes
have been unyielding to the development of small
molecule inhibitors, not all structured RNA elements
are amenable to targeting with low molecular weight
ligands. If the currently known target space for bio-
logically active small molecules from natural product
sources is of any guidance, RNA targets certainly do
not appear among the low hanging fruits for drug
discovery. Nevertheless, the area of antiinfective
drugs provides a strong record for successful exam-
ples of RNA-directed inhibitors. The bacterial ribo-
some is the target for over half of all natural
products that are known to exhibit antibiotic activity
and the majority of these compounds interact pre-
dominantly with the rRNA components. While the
bacterial ribosome looms large as a paradigm of
structured RNA providing a valuable target for anti-
infective drugs, recently, a bacterial riboswitch RNA
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has been identified in an unbiased phenotypic screen
as the target for a new class of antibiotic lead com-
pounds.119 This wonderful example of modern
antibiotic discovery promises an exciting future for
RNA targets emerging in the exploration of novel
therapies for bacterial and viral infections.
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